Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about CEL-SCI Corporation
CEL-SCI Corporation News
CEL-SCI Corporation Quantitative Score
About CEL-SCI Corporation
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
CEL-SCI Corporation Financials
Table Compare
Compare CVM metrics with: | |||
|---|---|---|---|
Earnings & Growth | CVM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CVM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CVM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CVM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
CEL-SCI Corporation Income
CEL-SCI Corporation Balance Sheet
CEL-SCI Corporation Cash Flow
CEL-SCI Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
CEL-SCI Corporation Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.0083 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 0.0083 | Quarterly |
Historical Market Cap
Shares Outstanding
CEL-SCI Corporation Executives
| Name | Role |
|---|---|
| Mr. Geert R. Kersten Esq. | Chief Executive & Financial Officer, Treasurer and Director |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| Ms. Patricia B. Prichep | Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary |
| Mr. John Cipriano | Senior Vice President of Regulatory Affairs |
| Dr. Giovanni Selvaggi M.D. | Acting Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Geert R. Kersten Esq. | Chief Executive & Financial Officer, Treasurer and Director | Male | 1959 | 709.72K |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer | 1956 | 355.64K | |
| Ms. Patricia B. Prichep | Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary | Female | 1951 | 298.23K |
| Mr. John Cipriano | Senior Vice President of Regulatory Affairs | Male | 1942 | 249.59K |
| Dr. Giovanni Selvaggi M.D. | Acting Chief Medical Officer | -- |
CEL-SCI Corporation Insider Trades
| Date | 4 Dec |
| Name | KERSTEN GEERT R |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 8389 |
| Date | 30 Sep |
| Name | TALOR EYAL |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 260 |
| Date | 30 Sep |
| Name | PRICHEP PATRICIA B |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 466 |
| Date | 30 Sep |
| Name | KERSTEN GEERT R |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 570 |
| Date | 28 Jul |
| Name | Watson Robert Eugene |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 4000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Dec | KERSTEN GEERT R | Chief Executive Officer | Acquired | P-Purchase | 8389 |
| 30 Sep | TALOR EYAL | Chief Scientific Officer | Acquired | A-Award | 260 |
| 30 Sep | PRICHEP PATRICIA B | Chief Financial Officer | Acquired | A-Award | 466 |
| 30 Sep | KERSTEN GEERT R | Chief Executive Officer | Acquired | A-Award | 570 |
| 28 Jul | Watson Robert Eugene | Director | Acquired | A-Award | 4000 |